Literature DB >> 23506680

Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices.

G Agelis1, A Resvani, D Ntountaniotis, P Chatzigeorgiou, C Koukoulitsa, M E Androutsou, P Plotas, J Matsoukas, T Mavromoustakos, T Cendak, T Ukmar Godec, G Mali.   

Abstract

The present work describes the drug:membrane interactions and a drug delivery system of the novel potent AT1 blocker BV6. This designed analog has most of the pharmacological segments of losartan and an additional biphenyltetrazole moiety resulting in increased lipophilicity. We found that BV6:membrane interactions lead to compact bilayers that may in part explain its higher in vitro activity compared to losartan since such environment may facilitate its approach to AT1 receptor. Its high docking score to AT1 receptor stems from more hydrophobic interactions compared to losartan. X-ray powder diffraction (XRPD) and thermogravimetric analysis (TGA) have shown that BV6 has a crystalline form that is not decomposed completely up to 600°C. These properties are desirable for a drug molecule. BV6 can also be incorporated into a mesoporous silicate drug-delivery matrix SBA-15. The properties of the obtained drug-delivery system have been inspected by XRD, (13)C CP/MAS, TGA and nitrogen sorption experiments.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23506680     DOI: 10.1016/j.bbamem.2013.03.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.

Authors:  Harry Ridgway; Christos T Chasapis; Konstantinos Kelaidonis; Irene Ligielli; Graham J Moore; Laura Kate Gadanec; Anthony Zulli; Vasso Apostolopoulos; Thomas Mavromoustakos; John M Matsoukas
Journal:  Viruses       Date:  2022-05-11       Impact factor: 5.818

Review 2.  From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.

Authors:  John Matsoukas; Vasso Apostolopoulos; Anthony Zulli; Graham Moore; Konstantinos Kelaidonis; Kalliopi Moschovou; Thomas Mavromoustakos
Journal:  Molecules       Date:  2021-01-25       Impact factor: 4.411

3.  Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2.

Authors:  Harry Ridgway; Graham J Moore; Thomas Mavromoustakos; Sotirios Tsiodras; Irene Ligielli; Konstantinos Kelaidonis; Christos T Chasapis; Laura Kate Gadanec; Anthony Zulli; Vasso Apostolopoulos; Russell Petty; Ioannis Karakasiliotis; Vassilis G Gorgoulis; John M Matsoukas
Journal:  Comput Struct Biotechnol J       Date:  2022-04-09       Impact factor: 6.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.